HYUNDAI BIOLAND Co.,Ltd. (KOSDAQ:052260)
3,625.00
-55.00 (-1.49%)
At close: Jun 10, 2026
HYUNDAI BIOLAND Revenue
HYUNDAI BIOLAND had revenue of 38.23B KRW in the quarter ending March 31, 2026, with 13.45% growth. This brings the company's revenue in the last twelve months to 135.04B, up 8.54% year-over-year. In the year 2025, HYUNDAI BIOLAND had annual revenue of 130.51B with 9.19% growth.
Revenue (ttm)
135.04B
Revenue Growth
+8.54%
P/S Ratio
0.82
Revenue / Employee
396.01M
Employees
341
Market Cap
110.40B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 130.51B | 10.99B | 9.19% |
| Dec 31, 2024 | 119.52B | 22.80B | 23.57% |
| Dec 31, 2023 | 96.72B | -2.43B | -2.45% |
| Dec 31, 2022 | 99.15B | -3.65B | -3.55% |
| Dec 31, 2021 | 102.80B | 13.90B | 15.64% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Ahn-Gook Pharmaceutical | 330.05B |
| Cosmax Nbt | 308.56B |
| H.PIO | 266.01B |
| DongKoo Bio & Pharma | 242.08B |
| Kyung Dong Pharmaceutical | 198.27B |
| WITHUS PHARMACEUTICAL Co.,LTD. | 108.89B |
| OPTUS Pharmaceutical | 91.62B |
| KOREA PHARMA | 91.42B |